Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work (NASDAQ:VBIO)
· seekingalpha.com
Valion Bio (VBIO) Q1 2026 earnings call recap: NIAID-funded Entolimod GI-ARS milestones, GMP validation timeline, cash burn and catalysts—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...